University of Helsinki’s latest spinout company Moncyte is on a mission to personalise treatment of high cholesterol

The newest science-based spinout company from the University of Helsinki, Moncyte Oy has developed a unique technology that can revolutionise the treatment of high cholesterol and help more patients achieve their target cholesterol levels sooner.

The medical need for personalised and targeted cholesterol-lowering drug therapy is great. Cholesterol-lowering drugs are the most widely prescribed medicines in the world, and it is estimated that more than half of Europeans and North Americans have high cholesterol. However, there is currently no effective way for healthcare professionals to determine which patients need more effective drug therapies to lower their cholesterol. As a result, most patients with high cholesterol do not reach their target cholesterol levels.  READ MORE